Clinical trial · Observational
Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma
Novel Drugs (Immuno-modulating Agents, Protesome Inhibitors, Monoclonal Antibodies) After Allogeneic Transplant in Patients With Multiple Myeloma: an Observational Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian on patients submitted to allo-HSCT among Italian Transplant Centers GITMO. This study will evaluate all consecutive adult patients who received novel drugs after hematopoietic stem cell transplantation from related and unrelated donors between January 1, 2009 to December 31, 2018 in GITMO-affiliated Centers. This study will evaluate approximately 300 subjects (with competitive enrolment) from GITMO investigational centers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Stem Cell Transplant | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with Multiple myeloma
- description
- Adult with diagnosis of multiple myeloma treated with Allo-HSCT from related - HLA identical or volunteer unrelated donor or haploidentical related donor performed from January 1, 2009 to december 31, 2018
Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- these outcome measures will be assessed at 2 year from transplant
- description
- OS is defined as the time from transplant to the date of death due to any cause or to the last date the patient was known to be alive (censored observation) or to the date of the data cut-off for final analysis
Secondary outcomes (5)
- measure
- Progression Free Survival 1 (PFS1)
- timeFrame
- these outcome measures will be assessed at 2 year from transplant
- description
- PFS1 is defined as the time interval from allo-HSCT until the first disease progression or death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria Written and signed study informed consent Multiple myeloma Allogeneic transplantation from related - HLA identical Allogeneic transplantation from volunteer unrelated donor allogeneic transplantation from haploidentical related donor Myeloablative or reduced intensity conditioning regimen Exclusion Criteria Second or further allogeneic transplant Plasma cell leukemia Non measurable disease
References
Publications (0)
Data not yet available